bisantrene has been researched along with Hepatocellular Carcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, Y; Huang, Y; Jin, Y; Meng, J; Sun, M; Tang, J; Wang, B; Wu, J; Zhang, J; Zhang, Y | 1 |
| Clark, G; Coltman, CA; Kuhn, J; Myers, JW; Pocelinko, R; Sandbach, JF; Von Hoff, DD | 1 |
| Brown, TD; Cowan, JD; Fleming, TR; Shildt, RA | 1 |
3 other study(ies) available for bisantrene and Hepatocellular Carcinoma
| Article | Year |
|---|---|
RACK1 promotes the proliferation, migration and invasion capacity of mouse hepatocellular carcinoma cell line in vitro probably by PI3K/Rac1 signaling pathway.
Topics: Animals; Anthracenes; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Liver Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred Strains; Morpholines; Neoplasm Invasiveness; Neuropeptides; Phosphatidylinositol 3-Kinases; rac1 GTP-Binding Protein; Receptors for Activated C Kinase; Signal Transduction; Transfection | 2013 |
Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
Topics: Adult; Aged; Anthracenes; Antineoplastic Agents; Bone Marrow; Carcinoma, Hepatocellular; Drug Evaluation; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1981 |
Phase II trial of bisantrene in hepatocellular carcinoma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Anthracenes; Carcinoma, Hepatocellular; Diagnosis-Related Groups; Drug Evaluation; Female; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged | 1987 |